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SUMMARY
Herein, we report an oral cavity squamous cell carci-
noma (OCSCC) patient-derived xenograft (PDX) plat-
form, with genomic annotation useful for co-clinical
trial and mechanistic studies. Genomic analysis
included whole-exome sequencing (WES) and tran-
scriptome sequencing (RNA-seq) on 16 tumors and
matched PDXs and additional whole-genome
sequencing (WGS) on 9 of these pairs as a represen-
tative subset of a larger OCSCC PDX repository
(n = 63). In 12 models with high purity, more than
90% of variants detected in the tumor were retained
in the matched PDX. The genomic landscape across
these PDXs reflected OCSCCmolecular heterogene-
ity, including previously described basal, mesen-
chymal, and classical molecular subtypes. To
demonstrate the integration of PDXs into a clinical
trial framework, we show that pharmacological inter-
vention in PDXs parallels clinical response and ex-
tends patient data. Together, these data describe a
repository of OCSCC-specific PDXs and illustrate
conservation of primary tumor genotypes, intratu-
moral heterogeneity, and co-clinical trial application.
INTRODUCTION
Oral cavity squamous cell carcinomas (OCSCCs) are a global
health problem, with more than 500,000 reported cases per
year. Despite major advances in surgical techniques and
chemo-radiotherapy, outcomes for patients with locally
advanced disease have remained unchanged at 30% local or
regional disease recurrence, 25% distant metastases, and
40% overall 5-year survival (Chinn and Myers, 2015; Zhang
et al., 2013). Molecular characterization using next-generation
sequencing has broadened our understanding of common
OCSCC genomic alterations and carcinogenesis (Cancer
Genome Atlas Network, 2015; India Project Team of the Interna-
tional Cancer Genome Consortium, 2013; Pickering et al., 2013).
Precision medicine approaches targeting specific pathways
implicated in OCSCC are in early stages, with validation studies
pending for a number of oncogenic dependencies (Hammerman
et al., 2015). These large-scale studies would benefit from addi-
tional insight obtained using in vivomodels that capture the com-
plex genetic background of OCSCC.
Patient-derived xenografts (PDXs) represent a high-fidelity,
personalized model for pre-clinical testing and validation of tar-
geted therapeutics (Hammerman et al., 2015; Hidalgo et al.,
2014). In addition, they provide a valuable resource for the study
of intratumoral heterogeneity and clonal dynamics (Eirew et al.,
2015; Hammerman et al., 2015; Hidalgo et al., 2014). A recent
study of more than 1,000 diverse tumor xenografts integrated
into a PDX clinical trial (PCT) framework revealed the fidelity of
xenografts in confirming multiple genotype relationships with
drug sensitivities (Gao et al., 2015). This study included seven
PDXs derived from head and neck squamous cell carcinomas
(HNSCCs). Three studies have reported initial engraftment rates
for HNSCCPDXs ranging from 17%–80%but included the use of
distinct immunodeficient mouse strains (Keysar et al., 2013;
Li et al., 2016; Peng et al., 2013). Another study analyzed gene
expression of matched primary tumors and PDXs showing vari-
able levels of conservation, but this was limited to three cases
(Guo et al., 2016; Peng et al., 2013). Interestingly, studies in
larger HNSCC PDX cohorts have shown that engraftment suc-
cess has no relation to pathologic stage or clinical behavior of
the primary tumor (Keysar et al., 2013; Li et al., 2016). Large
PDX collections are critical to capturing the population-wide
genomic alterations that are obscured in analysis of smaller
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cohorts (Gao et al., 2015). However, existing OCSCC-specific
PDX models have not been comprehensively defined to suffi-
ciently depict the heterogeneous disease landscape.
Herein we describe a cohort of OCSCC xenografts derived
from patients who have undergone standard-of-care surgery or
who enrolled in neoadjuvant trametinib or pembrolizumab clin-
ical trials. We performed sequencing analysis on 16 case-
matched tumors and PDXs, which displayed genomic and tran-
scriptomic fidelity to their respective tumors. While maintaining
the mutational landscape displayed in their matched primary
tumors, these PDXs also captured the molecular and genomic
diversity of OCSCC at the cohort level. Our study also reports
a larger OCSCC PDX repository (n = 63), which includes the
subset (n = 16) with comprehensive molecular annotation re-
ported here, that will serve as a platform for evaluating novel
therapeutic approaches as well as deepen our understanding
of the genomic and transcriptomic parallels between tumors
and PDXs.
RESULTS
Generation of Xenografts
In 2013, we initiated a PDX study for OCSCC across 114
patients from three cohorts: treatment-naive primary OCSCC
patients undergoing standard-of-care primary resection (n =
84), patients enrolled in a neoadjuvant trametinib clinical trial
(ClinicalTrials.gov: NCT01553851; n = 20) (Uppaluri et al.,
2017), and patients enrolled in a neoadjuvant pembrolizumab
clinical trial (ClinicalTrials.gov: NCT02296684; n = 10, data not
published). PDXs were attempted from treatment-naive tumor
samples from all patients (n = 114), post-treatment surgical
resections from patients enrolled in the trametinib clinical trial
(n = 20) or the pembrolizumab clinical trial (n = 10), and patients
with relapsed disease (n = 3). Overall, establishment of passage
0 (P0)-generation xenografts was successful in 63 tumor
samples, including 45 of 114 (39.4%) treatment-naive, 10 of 20
(50%) post-trametinib treated, 5 of 10 (50%) post-pembrolizu-
mab treated, and 3 relapse (Tables 1 and S1). PDXs were har-
vested once the tumor size reached 2 cm3, with a median time
to harvest of 85 days (range, 27–281 days).
Because our goal was to develop aPDX repository for genomic
and functional studies, we collected clinical and pathologic infor-
mation only on samples that successfully engrafted as P0 PDXs.
Demographics showed that 46 tumor specimenswere frommale
patients and 17 tumor specimens were from female patients
(Tables 1andS1). PDXswere successfully established for 3 stage
I and II, 10 stage III, and 32 stage IV primary (treatment-naive) tu-
mors. At time of biopsy or surgery, patients were 18–87 years of
age (median, 63 years). In addition, the xenograft time to harvest,
when used as a measure of how aggressively the xenograft
grows, was not significantly different across tumor stages. Path-
ologic evaluation of the PDXs was consistent with squamous cell
carcinoma histology (data not shown).
Genomic Analysis
Clinicopathological Summary of Sequenced Samples
We selected 16 PDXs (25%of the repository) formolecular anno-
tation using whole-genome sequencing (WGS), whole-exome
sequencing (WES), and/or transcriptome sequencing (RNA-
seq). WES and RNA-seq were obtained for 16 case-matched
tumors and P0 PDXs; WGS was obtained for 9 matched tumors
and PDXs (Tables 1 and S1). Of these 16 xenografts, 13 were
derived from primary untreated tumors, 1 was derived from a
relapse tumor, and 2 were derived from a paired primary and
relapse tumor. The cohort of sequenced PDXs did not signifi-
cantly differ from the larger cohort of established OCSCC
PDXswith regard to stage, age, and gender. There was no signif-
icant difference in the xenograft time to harvest between the
sequenced PDXs and the remainder of the cohort.
Mouse Contamination in Xenografts
Mouse cells were not sorted from PDX samples prior to nucleic
acid isolation for sequencing. Xenograft purity was defined as
the percentage of sequencing reads that specifically align to
the human reference genome in comparison with the mouse
reference genome. Mouse contamination was highest in WGS
data (9.7%–55.6%mouse-specific reads), followed by RNA-seq
(5.4%–39.7%) and finally exome data (0.7%–35%), reflecting the
successful enrichment of human DNA by the hybridization-
based capture reagent (Figure S1). A negligible number of reads
were classified as ‘‘both,’’ ‘‘neither,’’ or ‘‘ambiguous’’ on the ba-
sis of the level of certainty that reads map to either human
genome,mouse genome, or neither. Reads classified as ‘‘mouse
specific,’’ ‘‘both,’’ ‘‘neither,’’ or ‘‘ambiguous’’ were filtered out of
Table 1. Clinical Summary of Patient Samples
Repository
(n = 63)
Sequenced
Subset (n = 16)
Patient Cohort
Standard-of-care resection 34 (54%) 6 (38%)
Trametinib trial 22 (35%) 10 (63%)
Pembrolizumab trial 7 (11%) –
Tumor Status
Treatment-naive 45 (71%) 14 (88%)
Post-treatment 15 (24%) –
Relapse 3 (5%) 2 (13%)
Stage
I 3 (5%) –
II 2 (3%) –
III 12 (19%) 3 (19%)
IV 45 (71%) 13 (81%)
Age (years)
Below 40 4 (6%) 2 (13%)
40–59 22 (35%) 6 (38%)
60–79 29 (46%) 7 (44%)
Over 80 8 (13%) 1 (6%)
Gender
Male 46 (73%) 12 (75%)
Female 17 (27%) 4 (25%)
Overall, 63 PDXs were generated from 53 patients. In some cases, mul-
tiple PDXs were derived from the same patient at various time points.
Numbers (n) reflect number of xenografts associated. Refer to Table S1
for additional information.
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the sequencing data, and all subsequent analysis was performed
on the reads classified as ‘‘human specific.’’
Sequencing Results
WGSmedian sequence coverage was 263 for PDXs, 753 for tu-
mors, and 373 for normal samples. WES resulted in at least 203
coverage over an average of 91.5% of the targeted exome in
PDXs, 96.6% in tumors, and 95.2% in normal samples and an
average depth of 82.43 in PDXs, 81.23 in tumors, and 66.23
in normal samples. The total number of reads generated by
RNA-seq ranged from 89.5 million to 767million, with an average
of 391 million reads in tumor samples and 226 million reads in
PDX samples. Metrics for PDXs correspond to human-specific
reads, after competitive alignment with the mouse genome.
The Landscape of Somatic Mutations Is Conserved in
Most OCSCC PDXs
Somatic alterations detected by WGS, WES, and/or RNA-seq
were compared for the 16 pairs of OCSCC PDXs and case-
matched tumors. There were 2,414 non-silent coding single-
nucleotide variants (SNVs) and small insertions and deletions
(indels) detected in 14 primary tumors (Table S2; Figure S2A).
Of these, 1,929 (79.9%) were also identified in matched PDXs
with sufficient coverage (203) and variant allele fraction (VAF;
5%). Our somatic validation pipeline subjects variant calling to
additional filtering on the basis of sequencing coverage and
read support. Variants were identified independently in tumors
and PDXs, and then the union of these events was re-analyzed
in both samples to detect and recover variants with low
sequencing coverage and/or VAF. An additional 231 variants
(9.6%) originally detected in primary tumors were accounted
for in the PDXs. Overall, 89.5% of all variants identified in primary
tumors were also detected in their matched PDXs (Figures 1A
and 1B). In the 2 relapse tumors, 220 non-silent SNVs and indels
were identified; however, 119 (54.1%) were confirmed in
matched PDXs, and only 19 (8.6%) were recovered by reducing
sequencing depth and VAF filters. Overall, only 62.7%of variants
detected in relapse tumors and their matched PDXs were shared
(Figures 1A and 1B).
PDXs were compared with their respective tumors on the ba-
sis of the percentage of tumor variants maintained in their
respective PDXs and linear regression across the VAF distribu-
tions (Figure 1C). This analysis was restricted to variants that
had at least 203 coverage in both tumor and PDX samples.
Twelve PDXs (75%) retained at least 90% of the variants
detected in their respective tumors. Two of the remaining four
tumors (patients 2 and 6 primaries) had relatively higher corre-
lation in VAF distribution (R2 = 0.788 and 0.697, respectively)
of shared variants, the other two (patient 15 primary, patient
14 relapse) had the lowest correlation coefficients (R2 = 0.174
and 0.227, respectively) but also had much lower tumor cellu-
larity in the tumor sample (less than 50%). Overall, the correla-
tion in VAF distribution was lower in relapse cases (0.23–0.73;
median, 0.48; n = 2) than primary cases (0.17–0.84; median,
0.65; n = 14). However, these aggregate metrics are reduced
because of the cellularity of patient 14’s relapse tumor, which
had the lowest tumor purity (25%).
We next evaluated our PDX cohort for conservation of variants
in previously described significantly mutated genes for the
HNSCC TCGA (The Cancer Genome Atlas) cohort (Cancer
Genome Atlas Network, 2015). There were 47 mutations identi-
fied across 12 of the genes described as significantly mutated
genes from the TCGA HNSCC cohort (Cancer Genome Atlas
Network, 2015), and 44 were detected in both tumors and
PDXs across 16 tumors (1–5 mutations per patient; median, 2).
The reported cohort included mutations in TP53 (n = 12 primary,
n = 2 relapse), NOTCH1 (n = 3 primary), KMT2D (n = 2 primary),
HRAS (n = 2 primary), FAT1 (n = 2 primary), CDKN2A (n = 4
primary, n = 2 relapse), CASP8 (n = 3 primary, n = 1 relapse).
Mutations were also detected in AJUBA, CUL3, FBXW7,
NSD1, and PIK3CA, each in only one primary sample. In 15
of these tumors, all putative driver mutations were preserved,
while indels in FAT1 were observed in either the relapse tumor
or PDX from patient 14. Despite variance in the correlation
coefficient across the cohort, putative drivers that have been
previously described in HNSCC were maintained (Table S2;
Figure S2).
OCSCC PDXs Do Not Exhibit Rapid Accumulation of
Mutations Post-engraftment
In order to evaluatewhethermutations could have been acquired
after engraftment, we identified variants in PDXs that were unde-
tectable in the primary tumors. There were 149 PDX-specific
variants across the 14 primary PDXs, 76 (51%) of which were
expressed in the RNA; there were 41 PDX-specific variants de-
tected in 2 relapse PDXs, 20 (48.8%) of which were expressed
in the RNA (Figure 1B). Of the 190 variants exclusively detected
in PDXs, 4 (2.1%) had 0–203 coverage in their respective tu-
mors, but the coverage of the genomic positions of PDX-specific
variants in tumors (0–6723; median, 1643) was not significantly
different from the coverage of these variants in PDXs (20–5253;
median, 88.53). Thirty-seven of the 190 variants (19.5%) were
detected at%5%VAF in the PDX. However, to consider whether
PDX-only mutations were acquired post-engraftment, we evalu-
ated the clinical significance and potential implication in tumori-
genesis. Of the 190 PDX-only variants, only 2 were described as
recurrently mutated in the TCGA cohort. Both variants were
frameshift indels in FAT1 in the patient 14 relapse PDXs, present
at 53% and 61% VAF, respectively. Only one of these was
expressed at the RNA level (32.3% VAF). It is important to note
that the patient 14 relapse tumor had the lowest purity (25%)
and had the second lowest correlation coefficient in VAF distri-
bution with its respective PDX.
Studies evaluating the genomic integrity of PDX models
across tumor types have described the selective pressure
and/or accumulation of mutations over several passages. In
order to address this question of selective engraftment and pres-
sure to acquire mutations via passaging, the parental xenograft
(P0) generated from patient 13 was passaged twice in NSG
mice. Three PDXs from the P2 generation were studied by
WES. Of the 104 variants detected in the primary tumor, 90
(86%) were detected in the parental PDX. Out of the 90 variants
confirmed in P0, 85–87 (94%–97%) were subsequently detected
in the P2 generation PDXs (Table S2). There were 7 variants
detected in the P0 PDX that were undetectable in the primary
tumor, 6 of which were also detected in all three P2 PDXs. There
were 11 variants detected in P2 PDXs that were not detected in
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either the primary tumor or the P0 PDX; 5 of these variants were
present in all P2 PDXs (VAF = 4.44%–27.78%). Six of these var-
iants were specific to one or two of the P2 PDXs, all present at
less than 10% VAF. However, overall, correlation across all var-
iants remained 0.85–0.88 between all PDXs and the primary
tumor.
Large and Focal Copy-Number Alterations Are Retained
upon Engraftment
Absolute copy number was calculated by comparing either
tumor or PDX data with matched normal data and evaluated
on the basis of 10 kb windows across the genome. In order
to evaluate whether copy-number alterations (CNAs) were
conserved at the genome-wide scale, we calculated the corre-
lation between all case-matched PDXs and tumors. The Pear-
son correlation coefficient between matched tumors and
PDXs ranged from 0.3 to 0.97 (median, 0.72; median, 0.08 for
unmatched samples; Figure 2A). We found that correlation
between samples was significantly higher in matched PDXs
and tumors than in comparison with any other pair of samples
(p = 2.88e-07; Figure 2B). There were six samples that had rela-
tively low Pearson correlation coefficients (r < 0.60). Of these
six samples, one (patient 14, relapse, r = 0.561) had low tumor
purity (25%). Two (patients 5 and 8) had very low correlation
coefficients (r = 0.034 and r = 0.049, respectively). Interestingly,
these two patients also had the highest mutational burdens
(n = 445 and n = 327, respectively). Lack of correlation might
again be attributable to lower cellularity and/or cases with large
Figure 1. Mutations Are Overall Conserved in PDXs
(A) Venn diagram of all variants detected in primary or relapse tumors and their respective PDXs.
(B) Alluvial plots displaying variants detected in either ‘‘tumor,’’ PDX, or ‘‘both.’’ Variants are labeled ‘‘detected’’ if they have sufficient sequencing depth (203) and
VAF (5%); ‘‘low coverage’’ or ‘‘low VAF’’ if they are detected but do not meet one of these filters; ‘‘undetected, low coverage’’ if they are undetected and have
insufficient coverage; and ‘‘undetected’’ if the variant is undetected at a position with sufficient coverage.
(C) Scatterplots displaying the correlation between PDX DNA VAF and tumor DNA VAF. Samples are designated ‘‘R,’’ corresponding to ‘‘relapse’’ samples.
Points are colored on the basis of which samples the variant was detected in; gray points indicate variants for which there was <203 coverage in either the
tumor or PDX sample. The R2 value (of common points with at least 203 coverage in both samples) is represented by the red value in the lower right-hand
corner of each plot. The linear regression line is indicated in red with boundaries showing the SD of points. The bar charts on the right of each plot indicate the
proportion of common versus sample-specific variants, as well as those with less than 203 coverage in either the tumor or matched xenograft sample (indicated
in gray).
Refer to Figure S2 and Table S2 for further details.
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numbers of somatic alterations possibly indicative of increased
genomic instability.
Recurrent CNAs included gains in chromosomes 8q (n = 7), 5p
(n = 5), and 3q (n = 4) and losses in chromosomes 8p (n = 6) and
3p (n = 5) (Figure S2B), consistent with previous studies (Cancer
Genome Atlas Network, 2015). We also evaluated genes known
to be contained in focal CNAs (Figures 2C and S2C). We de-
tected amplifications of CCND1 (n = 7), EGFR (n = 4), FGFR1
(n = 1), KRAS (n = 2), and PIK3CA (n = 2) and loss of CDKN2A/
CDKN2B (n = 6) in tumors and their respective PDXs. In most
cases, CNAs (segment mean > 3 for amplifications, segment
mean < 1.5 for loss) were detected in both tumor and PDX.
However, in a few cases, resolution of these copy-number
changes was not obtained in tumors, because of low
purity, but was detected in the PDX; for example, KRAS amplifi-
cation in patient 1 (Figure S2C) and CDKN2A/B loss in patients 1
and 7 (Figure 2C).
RNA-Seq Analysis Reveals Tumor-Infiltrating Cell
Populations
Mouse-specific reads were filtered in silico from the xenograft
RNA samples before aligning reads to the human genome. Prin-
cipal-component analysis (PCA) of matched tumor and xeno-
graft gene expression revealed distinct stratification of PDXs
and tumor samples (Figure 3A). Using a supervised analysis
comparing matched tumors and PDXs, there were 298 Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways and
Gene Ontology (GO) annotations that were significantly upregu-
lated in tumor samples (p < 0.001), 28 processes that were signif-
icantly downregulated in tumor samples (p < 0.001), and 14
KEGG pathways that were differentially regulated within tumor
and PDX samples (p < 0.001; Table S3). The top 10 most signif-
icantly upregulated processes in tumor samples consisted of
cellular processes specific to nontumor infiltrating cells, such
as ‘‘leukocyte migration,’’ ‘‘adaptive immune response,’’ and
Figure 2. Copy-Number Alterations Are Concordant in Matched PDXs and Tumors
(A) Correlation matrix displaying the Pearson correlation coefficient (calculated on the basis of the absolute copy-number segment mean across 10 kb
windows). Samples are sorted on the basis of unsupervised hierarchical clustering of the correlation coefficient. Red triangles correspond to matched tumors
and PDXs.
(B). Density plot showing differences in correlation coefficient between case-matched tumors and PDXs (red) versus any other comparison (blue). AWilcoxon test
was performed, comparing the correlation between case-matched PDXs and unmatched or distinct pairs of samples (p = 1.09e-08).
(C) Genes commonly altered at the copy-number level in HNSCC were analyzed with 100 kb windows on either ends of the gene. Red rectangles correspond to
the genomic positions of the indicated gene. Point color corresponds to sample. Copy number is indicated by absolute copy number on the y axis, and only
segments with median copy number > 3 or < 1.5 are indicated by color (according to sample source).
Refer to Figure S2 for further details.
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‘‘leukocyte chemotaxis’’ (Figure 3B). Pathways upregulated in
PDXs included those related to keratinization and epidermal
cell differentiation.
Independent of infiltrating cell populations, we predicted that
PDXs would behave most similarly to their matched tumors
compared with unmatched tumors. In order to address this
question, we removed the top 1% of genes contributing to
each principal component from the previous analysis. This
removed the most prevalent genes associated with infiltrating
cell populations in order to better evaluate genes associated
with tumor-intrinsic biology (n = 59,884 genes). Pearson correla-
tion coefficients ranged from 0.47 to 0.97 (median, 0.87)
for case-matched tumors and PDXs (Figure 4A). This was
significantly greater than the correlations drawn between un-
matched combinations of samples (0.29–0.97; median, 0.75;
p = 1.69e-09; Figures 4B and 4C).
PDXs Recapitulate the Molecular Heterogeneity of the
Disease
Previous studies have described diverse molecular subtypes in
HNSCC (Chung et al., 2004;Walter et al., 2013). The four HNSCC
molecular subtypes described by Walter et al. (2013) were
subsequently confirmed in the TCGA dataset—atypical (24%),
basal (31%), classical (18%), and mesenchymal (27%)—on the
basis of genes associated with each signature (Cancer Genome
Figure 3. Differential Expression Analysis Reveals Tumor-Infiltrating
Cell Populations
(A) PCA clustering of PDX (xenome-filtered) and primary tumor RNA samples.
(B) Pathway analysis is summarized by bar charts showing the p value (lighter
hue) and false discovery rate (FDR) q value (darker hue). Pathways are labeled
along the y axis; the number of genes annotated within each pathway is
indicated in parentheses.
Refer to Table S3 for further details.
Figure 4. Correlation across the Transcriptome Is Highest in
Matched Tumors and PDXs
(A) Correlation matrix displaying the Pearson correlation coefficient calculated
across the gene expression of 59,884 genes (FPKM). This included the whole
transcriptome with the exception of the top 1% of genes contributing to the
principal components in Figure 3. Red triangles indicate tiles corresponding to
case-matched tumors and PDXs.
(B) Density plot showing differences in correlation coefficient between case-
matched tumors and PDXs (red) versus any other comparison (blue).
(C) A Wilcoxon test was used to compare the correlation between case-
matched PDXs and unmatched or distinct pairs of samples.
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Atlas Network, 2015). Because of the genomic diversity
observed in our sequenced PDX cohort, we hypothesized that
our repository contained PDXs derived from tumors across these
molecular subtypes. To test this, we built a random forest classi-
fier to categorize our samples on the basis of the expression sig-
natures and previously reported molecular subtypes described
in the cohort of Walter et al. (2013) (Experimental Procedures).
Our classifier, built on 638 genes, successfully categorized
125 of 138 samples in the dataset of Walter et al. (2013), for an
overall accuracy of 90.6% (Table S4). When applied to the
TCGA HNSCC dataset, 243 of 277 samples (87.7%) were
correctly predicted within their previously published molecular
subtype, accurately classifying 62 of 68 atypical, 82 of 85 basal,
40 of 49 classical, and 59 of 75 mesenchymal tumors (Figure 5).
The most common incorrect classification involved identifying
previously reported mesenchymal tumors as basal (15 of 75).
When applied to the 16 OCSCC tumors in our study, 3 were pre-
dicted to be atypical (18.8%), 7 basal (43.8%), 2 classical
(12.5%), and 4 mesenchymal (25%) (Table S4). Recently,
HNSCC single-cell RNA sequencing characterized the ‘‘mesen-
chymal’’ expression signature as driven primarily by stromal
infiltrate (Puram et al., 2017). Two subpopulations of cancer-
associated fibroblasts (CAFs) contributed specific signatures,
and we evaluated whether the CAF gene signature was upregu-
lated in samples subtyped as ‘‘mesenchymal’’ from our classi-
fier. CAF genes (n = 412) were queried across the published
datasets (Walter et al., 2013, and TCGA) and our reported data-
set (WUSM). Samples classified in the mesenchymal subtype
displayed significantly increased relative expression in CAF-
associated genes compared with the atypical (p < 0.05 in all
datasets), basal (p < 0.05 in all datasets), and classical subtypes
(p < 0.01 in the Walter et al., 2013, and TCGA datasets).
PDX Parallels Clinical Response in a Trametinib
‘‘Co-clinical’’ Trial
Advantages of generating PDXs in coordinationwith clinical trials
include the ability to functionally dissect patient treatment re-
sponses, as well as discovering and validating therapeutic
mechanisms. Twenty-nine of the PDXs in this study were from
patients in clinical trials, 10 of which are included in the
sequenced cohort. As a validation of this approach and this
PDX repository, we evaluated the efficacy of trametinib in the
post-treatment PDX generated from patient 2 at the time of sur-
gical resection. This patient had a subjective clinical response
with a downstaging of tumor from a clinical T3N1M0 OCSCC
to pathologically staged T1N0 disease (Uppaluri et al., 2017).
The patient later developed a local recurrence and lung metas-
tasis and ultimately succumbed to this disease. We analyzed
WES and RNA-seq data from untreated and post-trametinib
treated PDX and primary tumor samples and WES from recur-
rence and lung metastasis biopsies.
The treatment-naive tumor biopsy and matched PDX have
been presented in this study alongwith the other primary tumors.
WES detected 123 SNVs and indels in the primary tumor, 92 of
which were detected in its derived xenograft (Figure 6A). The
post-treatment tumor sample had very low purity; only 20 of
Figure 5. Varied HNSCC Molecular Subtypes Successfully Engraft as PDXs
This heatmap contains genes (rows) corresponding to a single gene out of the 638 gene signature defining the four molecular subtypes in HNSCC. Each column
corresponds to a sample within each cohort. Fill color represents the gene median-centered (GMC) value of the respective gene expression within each dataset
(relative expression). Four hundred twelve genes associated with cancer-associated fibroblasts (CAFs) defined by Puram et al. (2017) were summarized by the
median GMC value of the 412 genes in the associated sample (denoted in CAF signature). Datasets shown include the Walter et al. (2013) dataset (used to build
the classifier), the TCGA dataset, and the 16 tumor RNA samples obtained at Washington University School of Medicine reported in this study (WUSM). Values in
‘‘predict’’ indicate the molecular subtype predicted by the random forest classifier described. Values in ‘‘published’’ indicate the molecular subtype documented
for each corresponding sample in the previously published datasets.
Refer to Table S4.
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the 123 variants detected in the primary, untreated tumor were
detected at less than 15% VAF (Table S2). However, in the
PDX corresponding to the post-treatment tumor sample, 83 var-
iants (67.5%) from the primary tumor were detected, as well as
14 new variants. A focal amplification of EGFR was observed
in the primary tumor, pre- and post-treatment PDXs, the recur-
rent tumor, and, despite low purity, the metastasis sample
(Figure 6B).
Because there appeared to be a clinical response in the
2 week ‘‘window’’ clinical trial, we askedwhether a longer course
of trametinib would result in clinical benefit using the PDXmodel.
Cohorts of mice engrafted with patient 2’s post-treatment PDX
were treated with an extended course of trametinib or vehicle
(n = 7 each). While the vehicle-treated mice showed
progressive tumor growth, trametinib treatment resulted in
reduction in tumor size over the first 50 days of treatment, fol-
lowed by outgrowth of all tumors (Figure 6C). Thus, this PDX
model displays responses consistent with the clinical findings
in the patient and illustrates that escape tumors can be further
studied to define the basis of response and resistance.
DISCUSSION
The PDX cohort in this study was focused exclusively on OCSCC
patients, capturing clinical, mutational, and gene expression
subtyping of the disease defined by molecular annotation of
25%of the available repository. Future studieswill involve further
genomic and molecular annotation of the remaining repository
(n = 47), with appropriate public accessibility to these data. By
comparing the genomic landscape of our PDX cohort to previous
studies, we show that we have successfully generated diverse
genotypes that span the phenotypic heterogeneity characteristic
of HNSCC. Known recurrently mutated genes (e.g., TP53,
CASP8, CDKN2A) and CNAs of chromosomes 3, 5, and 8 were
recurrently altered in our sequenced cohort and were confirmed
in their matched PDXs. In addition, driver events, including
Figure 6. Patient 2 PDX Parallels Clinical Response in a Trametinib ‘‘Co-clinical’’ Trial
(A) Variant allele frequency (VAF) of the y axis labels (right-hand side) and the x axis labels (across top) are indicated by each point. The upper triangle contains all
variants, either detected in the primary tumor (dark blue) or detected in a subsequent sample (green). The lower triangle contains only variants detected in the
primary tumor. Pearson correlation coefficient is indicated by the red value in the lower right-hand corner of each plot. Density plots along the diagonal indicate
the VAF density in the corresponding sample.
(B) Absolute copy number is plotted along the y axis. Each point corresponds to the segment mean calculated across 10 kb (per sample) windows within the
shown genomic coordinates. The EGFR locus is shown in red.
(C) Tumor growth comparison between vehicle-treated and trametinib-treated P2 xenografts.
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canonical hotspot mutations and amplifications of known onco-
genes (e.g., HRAS, PIK3CA) and inactivation and loss of tumor
suppressor genes, were confirmed in matched PDXs.
Previous studies have concluded that effective xenoengraft-
ment does not correlate with patient age or tumor stage, while
others have described the difficulty in engraftment of tumors
from patients with early-stage disease. We successfully estab-
lished PDXs from five patients with stage I or II disease (8% of
our overall cohort). However, because our focus was on devel-
oping a repository and we studied only successfully engrafted
tumors, we cannot comment on overall correlations of staging
and engraftment success.
In comparing our sequenced cohort with the previously
described molecular subtypes of the disease, our PDXs were
shown to be established from atypical (n = 3), basal (n = 7), clas-
sical (n = 2), and mesenchymal (n = 4) tumors. The molecular
subtype classifier in this study was trained and validated on pre-
viously published tumor expression data and likely includes tu-
mor-infiltrating cell populations and microenvironmental factors
of those tissues. We attempted to apply the classifier to the PDX
RNA samples in addition to the tumor RNA samples, but only
seven PDX samples (44%)were labeledwith the same classifica-
tion as their matched tumor. The random forest classifier labels
samples by assigning a probability that a sample fits into a sub-
type, and these values were more marginal in PDX samples than
in the tumor RNA samples. Discordant labels could also reflect
issues in tumor purity. Future studies are necessary to describe
how these molecular subtype classifications can be applied (or
re-trained) to appropriately stratify large PDX cohorts. Recent
studies using single-cell transcriptomics (scRNA-seq) have
shown that themesenchymal subtype of HNSCC is due primarily
to infiltrating stromal cells, specifically CAFs (Puram et al., 2017).
Without assessing our tumor samples at single-cell resolution,
we cannot definitively attribute the mesenchymal signature in
our classifier to non-tumor cell populations. However, we did
observe significantly increased expression in these genes in
samples classified as ‘‘mesenchymal’’ compared with other
molecular subtypes. Future studies would benefit from addi-
tional scRNA-seq experiments to improve molecular subtyping
of tumor-intrinsic patterns in HNSCC, while accounting for stro-
mal infiltration.
Although our sequenced cohort captures genomic alterations
at the population level, this study also showed how effectively
OCSCC PDXs individually recapitulate their respective tumors.
This establishes the potential utility of our repository to explore
mechanisms of targeted drug sensitivity and resistance for pre-
cision oncology applications. Concordance was described in
terms of the maintenance of mutations and genomic alterations
in PDXs. At the individual level, most xenografts clearly displayed
strong conservation of these alterations with their matched tu-
mors. Previous studies have described selective environmental
pressures in PDXs across tumor types, observing subclonal
outgrowth or the selective engraftment of a subpopulation of
cells. However, in this study comprising PDXs specifically from
the P0 generation, 89.5% of all variants detected in primary
tumors were retained in their matched PDXs.
There were four PDXs that did not retain at least 90% of the
variants detected in their respective tumors. However, two of
these still had relatively high correlation in VAF distribution of
shared variants (R2 = 0.697–0.788), and the other two tumors
had low tumor cellularity, which led to lower correlation coeffi-
cients in paired samples. Technical and biological contributions
to lower correlation include sampling noise in sequencing data,
causing higher variance in the VAF distribution; tumor purity,
reducing the sensitivity for detecting somatic mutations; and
increased mutational burden, indicative of carcinogen-induced
tumors and genomic instability and resulting in increased
subclonal and private mutations. It is possible that a more com-
plex subclonal architecture could be resolved with increased
sequencing depth, single-cell sequencing analysis, or further
passaging to evaluate for subclonal selection. These additional
experiments would account for differential engraftment of tumor
cell subpopulations. Importantly, even in PDX-primary pairs with
low correlation metrics, all mutations in putative driver genes
were retained in the corresponding PDX in 15 cases.
The challenges contributing to low correlationmetrics inmuta-
tional frequency (i.e., tumor purity, increased genomic instability,
and lack of resolution of clonality) apply to copy-number detec-
tion as well. We observed concordance (Pearson correlation
coefficient = 0.47–0.97) in 13 cases and very low correlation
values (0.02–0.05) for 3 samples. Two of these samples, patients
5 and 8, were the most highly mutated and displayed increased
genomic instability. Single-cell resolution approaches may
clarify whether CNAs created a selective advantage for
engraftment.
Many PDX-specific mutations (55.3%) were missed in the
tumor because of low sequencing coverage or were present at
lower than 5% VAF in the xenograft. This indicates that either
there was not enough coverage to identify the variant in the
tumor, or it may have been acquired in a very small number of
cells after engraftment. In addition, we evaluatedWES from three
P2 xenografts derived from one of our P0 xenografts, and only 11
total mutations were detected specifically in P2 xenografts, 5 of
which were present at similar frequencies across the three P2
xenografts, suggesting that they may have been selected within
the P1 generation. Additional studies of a larger cohort of later
passage PDXs is needed to confidently evaluate whether
OCSCC PDXs generally retain the primary tumors’ genomic
landscape through passages. However, our dataset does not
overall exhibit aggressive mutational accumulation in early pas-
sages. In 15 of 16 cases, mutations in the all reported recurrently
mutated genes were maintained. However, in the patient 14
relapse tumor, there were two mutations in FAT1 in the PDX
and a tumor-specific FAT1mutation. It would requiremore tumor
sample or deeper sequencing in order to identify whether this
mutation was present at lower frequencies in the tumor, because
the purity of this tumor was about 25%. Althoughwe see concor-
dance across drivers, this example emphasizes the known fact
that selective pressure in the mice does sometimes fundamen-
tally alter tumor biology, and identifying these underlying differ-
ences is important when using PDXs.
As expected, unsupervised approaches to gene expression
analysis revealed the presence of non-tumor cells in bulk primary
tumor RNA data. Supervised differential expression analysis
directly comparing tumors with PDXs validated this observation,
revealing the upregulation of cellular processes associated with
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non-tumor cells (e.g., leukocyte migration, and adaptive immune
response). Downregulated pathways in tumors, on the other
hand, included cellular processes such as keratinization and
epidermal cell differentiation. This is likely indicative of tumor pu-
rity and non-tumor cell infiltration, because PDXs represent
a purer tumor cell population derived from squamous cell
carcinoma tissue. When genes associated with these cellular
processes were removed, we found that PDXs behaved most
similarly to their matched tumors. This is consistent with other
studies focused on characterizing HNSCC PDXs, using prote-
omics and immunohistochemistry, that show conservation of
oncogenic pathway activation and biomarker expression (Key-
sar et al., 2013; Li et al., 2016).
This study presents the advantages of PDX models as a bio-
logical and translational platform for studying OCSCC. At the
disease level, we see that the known molecular heterogeneity
is captured within the described PDX cohort. More importantly,
however, we validate the use of these models in a patient-
specific context, demonstrating strong concordance between
PDX and primary tumors and conservation of key putative driver
events. We describe a patient (patient 2) who responded to tra-
metinib in a neoadjuvant window clinical trial and show that
treatment of the patient’s PDX with trametinib demonstrates a
significant response closely reflecting the clinical history. For
this reason, we emphasize not only the PCT framework but
also the integration of PDXs into a co-clinical trial approach.
The time frame required to generate PDXs does not make it
feasible to study a PDX during the course of patient diagnosis
and treatment. However, by generating PDXs in conjunction
with patients enrolled in these neoadjuvant trials, we can
compare the course of tumorigenesis with clinical outcomes
and retrospectively studymechanisms of drug response. Our re-
pository contains PDXs derived from tumor samples at various
stages and time points in disease, including 29 from patients
enrolled in clinical trials. Future studies will further demonstrate
utility of our PDX platform as a resource for biomarker discovery,
novel combinations, and targeted therapies, as well as imple-
mentation for mechanistic studies.
EXPERIMENTAL PROCEDURES
Sample Acquisition
The tumor acquisition protocol, clinical trials, and correlative studies were all
approved by the Washington University Human Research Protection Office
and Animal Studies Committee, respectively. After informed consent, samples
were obtained through two methods: (1) OCSCC patients undergoing surgical
biopsy or resection were recruited as part of the Washington University tumor
banking protocol (institutional review board [IRB]: 201102323), or (2) patients
were recruited for neoadjuvant clinical trials with either the MEK inhibitor tra-
metinib (ClinicalTrials.gov: NCT01553851; IRB: 201205124) (Uppaluri et al.,
2017) or pembrolizumab (ClinicalTrials.gov: NCT02296684; IRB: 201412118).
Xenoengraftment Procedures
Tumor biopsies were obtained from patients and maintained in sterile DMEM
containing 10% fetal calf serum (FCS) and 1% amphotericin. Biopsies were
sectioned using razor blades into four separate pieces, one specifically for
xenograft generation. Briefly, fresh tumor was minced into approximately 16
pieces, ranging from 2 to 8 mm3, and transferred on ice to the animal facility.
Six- to 8-week-old NOD-scid ILRgnull (NSG) mice (The Jackson Laboratory)
were anesthetized and shaved, and four small incisions were made, one on
each quadrant of the flank. Tumor pieces were then saturated with Matrigel
(Corning), and four pieces were transferred subcutaneously into each quad-
rant using sterile forceps. See Supplemental Experimental Procedures for
further details on xenoengraftment, mouse maintenance, and treatment.
Sequencing and Data Analysis
Genomic DNA was isolated by the Siteman Cancer Center Tissue Processing
Core using the DNeasy Blood and Tissue Kit (QIAGEN). Library construction
and sequencing were performed as previously described, with a few excep-
tions described in the Supplemental Experimental Procedures (Griffith et al.,
2015a). Total RNAwas isolated by the Siteman Cancer Center Tissue Process-
ing Core using QIAGEN RNeasy kits. Single-indexed RNA sequencing
(RNA-seq) libraries were prepared using the Illumina TruSeq Stranded Total
RNA kit with 500 ng of starting material according to the manufacturer’s rec-
ommendations. Sequencing was performed on either the Illumina HiSeq
2500 V4 1 TB platform (2 3 125 bp reads) or the Illumina HiSeq 4000 platform
(2 3 150 bp reads).
Removing Contaminant Mouse Reads from Xenograft Data
WGS, WES, and RNA-seq reads from xenografts were aligned competitively
against the human reference genome (National Center for Biotechnology Infor-
mation [NCBI] build 38, GRCh38) and the mouse reference genome (Genome
Reference Consortium Mouse Build 38, mm10) using the Xenome (version
1.0.0) software in order to filter mouse reads from human reads (Conway
et al., 2012). Subsequent somatic variant detection was performed on data
excluding the mouse-mapped reads.
Sequence Alignment and Somatic Event Detection
The Genome Modeling System (GMS) was used for all analysis, including the
somatic variant detection and RNA-seq analysis (Griffith et al., 2015b). Briefly,
WGS andWES data were processed through SpeedSeq version 0.1.0 (Chiang
et al., 2015; Faust and Hall, 2014), which aligns reads using BWA-MEM version
0.7.10 (Li, 2013) to the human reference genome (NCBI build 38, GRCh38) and
marks duplicates using SAMBLASTER version 0.1.22 (Faust and Hall, 2014).
RNA reads were aligned to GRCh38 using TopHat version 2.0.8 (Trapnell
et al., 2009). Somatic variants were predicted using several variant callers by
comparing primary tumor or xenograft with matched normal pairs. SNVs and
small indels were detected and annotated using the GMS transcript variant
annotator against Ensembl version 74. See Supplemental Experimental Pro-
cedures for more details. All SNVs and indels were manually reviewed for
removal of false positives according to standard procedures (Barnell et al.,
2018). Somatic CNAs were detected by CopyCat version 0.1 (https://github.
com/chrisamiller/copyCat), and structural variations were predicted using
Manta version 0.29.6 (Chen et al., 2016). Tumor purity was estimated by the
mode of minor allele frequencies in regions of loss of heterozygosity (LOH),
as previously described (Anagnostou et al., 2017). SciClone was used to
assess the clonality of mutations present in copy neutral and non-LOH regions
(Miller et al., 2014).
Gene Expression and Pathway Analysis
Gene expression levels were quantified using Cufflinks version 2.1.1(Trapnell
et al., 2010) and HTSeq-count version 0.5.4p1 (Anders and Huber, 2010). Dif-
ferential expression analysis was performed using the DESeq2 R package
(Love et al., 2014) on gene raw counts generated using HTSeq, and gene
expression pathway analysis was performed using the GAGE R package
(Luo et al., 2009).
Analysis of Published Expression Data and Random Forest
Classification
The microarray probe-level intensity files (containing log2-transformed, nor-
mexp background-corrected, LOESS-normalized values) from Walter et al.
(2013) (GEO: GSE39366; n = 138) were gene median-normalized. Gene
expression data (FPKM [fragments per kilobase of transcript per million map-
ped reads]) from the TCGA HNSCC cohort (n = 277) were log2-transformed
and gene median-normalized (Cancer Genome Atlas Network, 2015). The ran-
domForest R package version 4.6-12 was used to build a classifier using 638
Ensembl gene identifiers previously used to define the fourmolecular subtypes
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of HNSCC and trained on the dataset of Walter et al. (2013) (GEO: GSE39366)
on the basis of their previously reported molecular subtypes. This classifier
was subsequently validated on the TCGA dataset and used to predict gene
expression subtypes in the reported dataset (WUSM; n = 16). The infiltration
of CAFs was interrogated by summarizing the expression of 412 CAF-
associated genes within the three datasets (Walter et al., 2013, TCGA, and
WUSM). For further details, see Supplemental Experimental Procedures.
Statistical Methods
Clinicopathological comparisons were conducted using chi-square tests or
one-way ANOVA as appropriate. All statistics and data visualization were per-
formed in R version 3.3.2. using the ggplot2 R package (version 2.2.1) (Wick-
ham, 2009) and GenVisR version 1.8.0 (Skidmore et al., 2016). Concordance of
expression and CNA was determined using the Pearson correlation, and VAF
distribution between PDXs and matched tumors was summarized using the
coefficient of determination.
DATA AND SOFTWARE AVAILABILITY
The accession number for the sequencing data reported in this paper is data-
base of Genotypes and Phenotypes (dbGaP): phs001623.v1.p1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and four tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.07.058.
ACKNOWLEDGMENTS
We thank all patients and their families for participating in our tumor banking
and clinical trials protocols. We thank D.N. Hayes and V. Walter for sharing
the gene classifier data. L.D.W. is supported by the National Cancer Institute
(NIH NCI K08 CA166229, P30 CA91842, K22 CA188163). M.G. is funded by
the National Human Genome Research Institute (NIH NHGRI R00
HG007940). The Siteman Cancer Center is supported in part by an NCI Cancer
Center Support Grant (NIH NCI P30 CA91842, T. Eberlein, principal investi-
gator). R.U. is funded by the National Comprehensive Cancer Network
Oncology Research Program, general research support provided by Novartis
Pharmaceutical Corporation (Novartis), and the National Institute of Dental and
Craniofacial Research (NIH NIDCR R01 DE024403). O.L.G. is funded by the
National Cancer Institute (NIH NCI K22CA188163 and NIH NCI U01
CA209936) and a Cancer Research Foundation Young Investigator Award.
Part of this work was performed as part of the Washington University School
of Medicine Genomics Tumor Board, which was funded with private research
support from the Division of Oncology and the McDonnell Genome Institute.
AUTHOR CONTRIBUTIONS
T.L., P.Z., A.E.W., J.H.L., and R.U. processed tumor samples and generated
xenografts. D.R.A. and R.U. provided clinical supervision. K.M.C., E.K.B.,
and Z.L.S. performed the genomic analysis, which was supervised by
E.R.M., L.D.W., M.G., and O.L.G. P.Z. and T.L. collated clinical data, per-
formed the trametinib studies, and acquired DNA and RNA from all specimens.
R.D.C. performed all pathologic analysis related to primary tumors and PDXs.
K.M.C., R.U., and O.L.G. wrote the initial draft, and all authors edited and
approved the final draft. R.U. and O.L.G. supervised the study.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: November 28, 2017
Revised: May 16, 2018
Accepted: July 16, 2018
Published: August 21, 2018
REFERENCES
Anagnostou, V., Smith, K.N., Forde, P.M., Niknafs, N., Bhattacharya, R.,White,
J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. (2017). Evolution of neoan-
tigen landscape during immune checkpoint blockade in non-small cell lung
cancer. Cancer Discov. 7, 264–276.
Anders, S., and Huber,W. (2010). Differential expression analysis for sequence
count data. Genome Biol. 11, R106.
Barnell, E.K., Ronning, P., Campbell, K.M., Krysiak, K., Ainscough, B.J., Ram-
irez, C., Spies, N., Kunisaki, J., Hundal, J., Skidmore, Z.L., et al. (2018). Stan-
dard operating procedure for somatic variant refinement of tumor sequencing
data. bioRxiv. https://doi.org/10.1101/266262.
Cancer Genome Atlas Network (2015). Comprehensive genomic characteriza-
tion of head and neck squamous cell carcinomas. Nature 517, 576–582.
Chen, X., Schulz-Trieglaff, O., Shaw, R., Barnes, B., Schlesinger, F., Ka¨llberg,
M., Cox, A.J., Kruglyak, S., and Saunders, C.T. (2016). Manta: rapid detection
of structural variants and indels for germline and cancer sequencing applica-
tions. Bioinformatics 32, 1220–1222.
Chiang, C., Layer, R.M., Faust, G.G., Lindberg, M.R., Rose, D.B., Garrison,
E.P., Marth, G.T., Quinlan, A.R., andHall, I.M. (2015). SpeedSeq: ultra-fast per-
sonal genome analysis and interpretation. Nat. Methods 12, 966–968.
Chinn, S.B., and Myers, J.N. (2015). Oral cavity carcinoma: current manage-
ment, controversies, and future directions. J. Clin. Oncol. 33, 3269–3276.
Chung, C.H., Parker, J.S., Karaca, G., Wu, J., Funkhouser, W.K., Moore, D.,
Butterfoss, D., Xiang, D., Zanation, A., Yin, X., et al. (2004). Molecular classifi-
cation of head and neck squamous cell carcinomas using patterns of gene
expression. Cancer Cell 5, 489–500.
Conway, T., Wazny, J., Bromage, A., Tymms, M., Sooraj, D., Williams, E.D.,
and Beresford-Smith, B. (2012). Xenome—a tool for classifying reads from
xenograft samples. Bioinformatics 28, i172–i178.
Eirew, P., Steif, A., Khattra, J., Ha, G., Yap, D., Farahani, H., Gelmon, K., Chia,
S., Mar, C.,Wan, A., et al. (2015). Dynamics of genomic clones in breast cancer
patient xenografts at single-cell resolution. Nature 518, 422–426.
Faust, G.G., and Hall, I.M. (2014). SAMBLASTER: fast duplicate marking and
structural variant read extraction. Bioinformatics 30, 2503–2505.
Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang,
C., Schnell, C., Yang, G., Zhang, Y., et al. (2015). High-throughput screening
using patient-derived tumor xenografts to predict clinical trial drug response.
Nat. Med. 21, 1318–1325.
Griffith, M., Miller, C.A., Griffith, O.L., Krysiak, K., Skidmore, Z.L., Ramu, A.,
Walker, J.R., Dang, H.X., Trani, L., Larson, D.E., et al. (2015a). Optimizing can-
cer genome sequencing and analysis. Cell Syst. 1, 210–223.
Griffith, M., Griffith, O.L., Smith, S.M., Ramu, A., Callaway, M.B., Brummett,
A.M., Kiwala, M.J., Coffman, A.C., Regier, A.A., Oberkfell, B.J., et al.
(2015b). Genome Modeling System: a knowledge management platform for
genomics. PLoS Comput. Biol. 11, e1004274.
Guo, S., Qian, W., Cai, J., Zhang, L., Wery, J.-P., and Li, Q.-X. (2016). Molec-
ular pathology of patient tumors, patient-derived xenografts, and cancer cell
lines. Cancer Res. 76, 4619–4626.
Hammerman, P.S., Hayes, D.N., andGrandis, J.R. (2015). Therapeutic insights
from genomic studies of head and neck squamous cell carcinomas. Cancer
Discov. 5, 239–244.
Hidalgo, M., Amant, F., Biankin, A.V., Budinska´, E., Byrne, A.T., Caldas, C.,
Clarke, R.B., de Jong, S., Jonkers, J., Mælandsmo, G.M., et al. (2014). Pa-
tient-derived xenograft models: an emerging platform for translational cancer
research. Cancer Discov. 4, 998–1013.
India Project Team of the International Cancer Genome Consortium (2013).
Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals
new recurrently-mutated genes and molecular subgroups. Nat. Commun. 4,
2873.
Keysar, S.B., Astling, D.P., Anderson, R.T., Vogler, B.W., Bowles, D.W., Mor-
ton, J.J., Paylor, J.J., Glogowska, M.J., Le, P.N., Eagles-Soukup, J.R., et al.
(2013). A patient tumor transplant model of squamous cell cancer identifies
Cell Reports 24, 2167–2178, August 21, 2018 2177
PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol. On-
col. 7, 776–790.
Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs
with BWA-MEM. arXiv, arXiv:1303.3997. https://arxiv.org/abs/1303.3997.
Li, H., Wheeler, S., Park, Y., Ju, Z., Thomas, S.M., Fichera, M., Egloff, A.M., Lui,
V.W., Duvvuri, U., Bauman, J.E., et al. (2016). Proteomic characterization of
head and neck cancer patient-derived xenografts. Mol. Cancer Res. 14,
278–286.
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
Luo, W., Friedman, M.S., Shedden, K., Hankenson, K.D., and Woolf, P.J.
(2009). GAGE: generally applicable gene set enrichment for pathway analysis.
BMC Bioinformatics 10, 161.
Miller, C.A., White, B.S., Dees, N.D., Griffith, M., Welch, J.S., Griffith, O.L., Vij,
R., Tomasson, M.H., Graubert, T.A., Walter, M.J., et al. (2014). SciClone: infer-
ring clonal architecture and tracking the spatial and temporal patterns of tumor
evolution. PLoS Comput. Biol. 10, e1003665.
Peng, S., Creighton, C.J., Zhang, Y., Sen, B., Mazumdar, T., Myers, J.N., Lai,
S.Y., Woolfson, A., Lorenzi, M.V., Bell, D., et al. (2013). Tumor grafts derived
from patients with head and neck squamous carcinoma authentically maintain
the molecular and histologic characteristics of human cancers. J. Transl. Med.
11, 198.
Pickering, C.R., Zhang, J., Yoo, S.Y., Bengtsson, L., Moorthy, S., Neskey,
D.M., Zhao, M., Ortega Alves, M.V., Chang, K., Drummond, J., et al. (2013).
Integrative genomic characterization of oral squamous cell carcinoma iden-
tifies frequent somatic drivers. Cancer Discov. 3, 770–781.
Puram, S.V., Tirosh, I., Parikh, A.S., Patel, A.P., Yizhak, K., Gillespie, S.,
Rodman, C., Luo, C.L., Mroz, E.A., Emerick, K.S., et al. (2017). Single-cell tran-
scriptomic analysis of primary and metastatic tumor ecosystems in head and
neck cancer. Cell 171, 1611–1624.e24.
Skidmore, Z.L., Wagner, A.H., Lesurf, R., Campbell, K.M., Kunisaki, J., Griffith,
O.L., and Griffith, M. (2016). GenVisR: Genomic Visualizations in R. Bioinfor-
matics 32, 3012–3014.
Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: discovering splice
junctions with RNA-Seq. Bioinformatics 25, 1105–1111.
Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren,
M.J., Salzberg, S.L., Wold, B.J., and Pachter, L. (2010). Transcript assembly
and quantification by RNA-Seq reveals unannotated transcripts and isoform
switching during cell differentiation. Nat. Biotechnol. 28, 511–515.
Uppaluri, R., Winkler, A.E., Lin, T., Law, J.H., Haughey, B.H., Nussenbaum, B.,
Paniello, R.C., Rich, J.T., Diaz, J.A., Michel, L.P., et al. (2017). Biomarker and
tumor responses of oral cavity squamous cell carcinoma to trametinib: a phase
II neoadjuvant window-of-opportunity clinical trial. Clin. Cancer Res. 23, 2186–
2194.
Walter, V., Yin, X., Wilkerson, M.D., Cabanski, C.R., Zhao, N., Du, Y., Ang,
M.K., Hayward, M.C., Salazar, A.H., Hoadley, K.A., et al. (2013). Molecular
subtypes in head and neck cancer exhibit distinct patterns of chromosomal
gain and loss of canonical cancer genes. PLoS ONE 8, e56823.
Wickham, H. (2009). ggplot2: Elegant Graphics for Data Analysis (New York:
Springer Science & Business Media).
Zhang, H., Dziegielewski, P.T., Biron, V.L., Szudek, J., Al-Qahatani, K.H.,
O’Connell, D.A., Harris, J.R., and Seikaly, H. (2013). Survival outcomes of pa-
tients with advanced oral cavity squamous cell carcinoma treated with multi-
modal therapy: a multi-institutional analysis. J. Otolaryngol. Head Neck
Surg. 42, 30.
2178 Cell Reports 24, 2167–2178, August 21, 2018
Cell Reports, Volume 24
Supplemental Information
Oral Cavity Squamous Cell Carcinoma Xenografts
Retain Complex Genotypes
and Intertumor Molecular Heterogeneity
Katie M. Campbell, Tianxiang Lin, Paul Zolkind, Erica K. Barnell, Zachary L.
Skidmore, Ashley E. Winkler, Jonathan H. Law, Elaine R. Mardis, Lukas D.
Wartman, Douglas R. Adkins, Rebecca D. Chernock, Malachi Grifﬁth, Ravindra
Uppaluri, and Obi L. Grifﬁth
SUPPLEMENTAL FIGURES 
Figure S1. Targeted sequencing methods exhibit lower levels of mouse contamination. Refer to Experimental Procedures. A-B. 
Bar charts displaying either the raw number or proportion of reads classified by Xenome as confidently 'Human' or 'Mouse,' or as 
'Both', 'Neither', or 'Ambiguous' for WGS (n=9), WES (n=16), or RNAseq (n=16) PDX samples. ​C-D. ​Distribution of the raw number 
or proportion of reads in each data type associated with each Xenome class. 
 
 
Figure S2. Somatic landscape across the sequenced PDX cohort. Refer to Figure 1. A. ​This waterfall plot shows recurrently 
mutated genes across the cohort of primary tumors and paired xenografts. The bar chart across the top shows the total number of 
nonsilent mutations identified across each case-matched PDX/tumor. Bars are filled to indicate the number of mutations detected in 
both tumor and PDX ('Common') or only one sample (‘Tumor Only’ or ‘PDX Only’). The waterfall plot indicates the type of mutation 
detected in each gene (y-axis) for each sample (x-axis). Borders around tiles indicate whether the mutation was only detected in either 
the tumor or PDX (‘Tumor Only’ or ‘PDX Only’). The horizontal bar chart on the left indicates the percentage of the cohort 
containing mutations in the indicated gene. ​B.​ Median absolute copy number was calculated across large chromosomal segments, and 
large copy number alterations were called across the genome. Colored tiles indicate the patient-associated samples. Within each row, 
the tumor is on the top and the xenograft is on the bottom. ​C.​ Genes commonly altered at the copy number level in HNSCC were 
analyzed with 100kb windows on either ends of the gene. Red rectangles correspond to the genomic positions of the indicated gene. 
Point color corresponds to sample, and copy neutral samples are indicated. Copy number is indicated by absolute copy number on the 
y-axis, and only segments with median copy number >3 or <1.5 are indicated by color (according to sample source). The horizontal 
dotted line at y=2 indicates copy neutral status. 
 
SUPPLEMENTAL TABLES 
Table S1. Overview of the reported PDX repository. Refer to Table 1. ​*X = xenograft/standard-of-care resection, T =  trametinib 
clinical cohort, P = pembrolizumab clinical trial cohort.  
Cohort* Patient Timepoint Treatment TNM Stage 
Age 
(yrs) Sex 
Days to 
Harvest Sequencing 
T 1 primary untreated T4aN0M0 IVA 74 M 105 WES,RNA 
T 1 posttreatment trametinib NA NA 74 M 65 None 
T 2 primary untreated T3N1M0 III 30 F 132 WGS,WES,RNA 
T 2 posttreatment trametinib T1N0M0 I 30 F 36 WES 
T 3 primary untreated T4aN1M0 IVa 45 M 85 WGS,WES,RNA 
T 3 posttreatment trametinib T4aN0M0 IVA 45 M 101 None 
X 4 relapse post-surgery T4bN2bMx IVB 55 F 111 WGS,WES,RNA 
X 5 primary untreated T4aN1Mx IVA 84 F 88 WGS,WES,RNA 
T 6 primary untreated T4aN2bM0 IV 65 M 117 WGS,WES,RNA 
T 6 posttreatment trametinib T4aN2bM0 IV 65 M 95 None 
X 7 primary untreated T2N1Mx III 56 F 93 WGS,WES,RNA 
X 8 primary untreated T3N2Mx IVA 18 M 90 WGS,WES,RNA 
X 9 primary untreated T2N1MX III 69 M 85 WGS,WES,RNA 
X 10 primary untreated T4aN2Mx IVA 47 M 38 WGS,WES,RNA 
T 11 primary untreated T3N2bM0 IVa 54 M 68 WES,RNA 
T 12 primary untreated T2N2bM0 IVA 78 M 44 WES,RNA 
T 12 posttreatment trametinib T1N1M0 III 78 M 27 None 
T 13 primary untreated T4N2M0 IVA 57 M 115 WES,RNA 
T 14 primary untreated T2N2bM0 IVA 75 M 247 WES,RNA 
T 14 posttreatment trametinib T1N2bM0 IVA 75 M 203 None 
T 14 relapse post-surgery rT4aN0 IVA 75 M 43 WES,RNA 
T 15 primary untreated T4N0M0 IVA 66 M 84 WES,RNA 
T 15 posttreatment trametinib T2N0M0 II 66 M 69 None 
X 16 primary untreated T4N2bM0 IVA 71 M 84 None 
X 17 primary untreated rT4aN0Mx IVA 81 F 44 None 
X 18 relapse post-surgery T4AN1Mx IVA 69 M 137 None 
X 19 primary untreated T4aN2Mx IVA 47 M 78 None 
X 20 primary untreated T4aN1Mx IVA 60 M 83 None 
X 21 primary untreated T4aN2Mx IVA 58 M 57 None 
X 22 primary untreated T3N0Mx III 54 M 38 None 
X 23 primary untreated T4aN2Mx IVA 50 M 59 None 
X 24 primary untreated T4aN0Mx IVA 64 M 81 None 
X 25 primary untreated T4aN0Mx IVA 39 M 165 None 
X 26 primary untreated pT3NxMx III 86 F 106 None 
X 27 primary untreated T1N0Mx I 60 M 217 None 
X 28 primary untreated T3N1Mx III 67 M 68 None 
X 29 primary untreated T2M0Mx III 43 M 111 None 
X 30 primary untreated T3N2Mx IVA 53 M 124 None 
X 31 primary untreated rT4N1M0 IVA 85 M 133 None 
X 32 primary untreated T1N0Mx I 61 M 98 None 
X 33 primary untreated T2N2Mx IVA 51 F 66 None 
X 34 primary untreated T4aN0Mx IVA 55 F 85 None 
X 35 primary untreated T4aNxM0 IVA 80 M 96 None 
X 36 primary untreated T4aNxMx IVA 58 F 76 None 
X 37 primary untreated pT4NxMx IVA 83 F NA None 
X 38 primary untreated T3N0Mx III 54 M NA None 
X 39 primary untreated T2N0 II 49 F 117 None 
X 40 primary untreated T3N2Mx IVA 71 F NA None 
X 41 primary untreated T4aN1Mx IVA 54 M 42 None 
X 42 primary untreated T3N1Mx III 79 F NA None 
X 43 primary untreated T4aN2bM1 IVC 64 F 76 None 
T 44 primary untreated T2N1M0 III 58 M 217 None 
T 45 primary untreated T4aN2CM0 IVa 63 M 281 None 
T 46 posttreatment trametinib T4aN0M0 IVA 63 M 82 None 
T 47 posttreatment trametinib T1N2bM0 III 59 M 65 None 
T 48 posttreatment trametinib T4aN2bM0 IVa 72 M 143 None 
P 49 posttreatment pembrolizumab T4N2C IV 60 M 57 None 
P 50 primary untreated T4N2B IV 87 M 110 None 
P 51 posttreatment pembrolizumab T4N2B IV 87 M 42 None 
P 52 posttreatment pembrolizumab T4N0 IV 72 F 50 None 
P 53 primary untreated T4N0 IV 73 M 98 None 
P 54 posttreatment pembrolizumab T4N1 IV 54 M 47 None 
P 55 posttreatment pembrolizumab T4N1 IV 69 F 44 None 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Xenoengraftment procedures 
Tumor biopsies were obtained from patients and and maintained in sterile Dulbecco Modified Eagle’s medium containing 10% Fetal 
Calf Serum (FCS) and 1% amphotericin. Biopsies were sectioned using razor blades into four separate pieces for the following 
purposes: (1) formalin fixation for storage and immunohistochemical analysis (2) flash freezing in liquid nitrogen for DNA and RNA 
extraction, (3) slow freezing in FCS containing 10% dimethyl sulfoxide (DMSO) for downstream experiments, and (4) immediate 
transplantation into mice for xenograft generation. 
Within one hour of acquisition, fresh tumor was immediately minced into approximately 16 pieces, ranging in size from 2-8 mm3, and 
transferred on ice to the animal facility. 6-8 week old NOD-scid ILRgnull (NSG) mice (Jackson Laboratory, Bar Harbor, ME) were 
anesthetized, shaved, and four small incisions were made, one on each quadrant of the flank. Tumor pieces were then saturated with 
Matrigel (Corning, Tewksbury, MA), and four pieces were transferred subcutaneously into each quadrant using sterile forceps. 
Mice were maintained on sterile water containing sulfamethoxazole (280 ug/mL) and trimethoprim (56 ug/mL) for one month after 
injection and monitored twice weekly for tumor growth. Successful establishment was defined as progressive tumor growth and 
tumors were harvested at approximately 2 cm3 tumor volume. Xenografts were resected and divided in the same manner as the 
primary tumors and were named the “P0” generation. In some cases, P0 generation tumors were slow-frozen in FCS+10% DMSO and 
thawed for subsequent engraftment of the P1 generation. 
Trametinib treatment of engrafted mice 
Trametinib (Selleckchem, Houston, TX) was dissolved in DMSO (10 mg/mL), and further diluted into sterile water containing 0.5% 
w/v hypromellose (Sigma-Aldrich, St. Louis, MO) and 2% v/v Tween-80 (Sigma-Aldrich, St. Louis, MO) to a concentration of 0.3 
mg/mL ​(Banks et al., 2015)​. Mice bearing successfully engrafted OCSCC tumors were treated with daily oral gavage with either 
trametinib (3 mg/kg), or vehicle alone beginning 7 days after implantation. Tumor dimensions were measured daily. 
Sequencing methods 
Library construction and sequencing were performed as previously described with a few exceptions described below​(Griffith et al., 
2015a)​. Single indexed libraries were constructed according to the manufacturer’s recommendations using the Illumina TruSeq Nano 
Kit (Illumina Inc, San Diego, CA) for whole genome sequencing (WGS) on the Illumina HiSeq X (2x150 bp reads). Genomic DNA 
was fragmented using the Covaris E210 DNA Sonicator (Covaris, WoBurn, MA). Dual indexed whole exome sequencing (WES) 
libraries were constructed/pooled according to the manufacturer’s recommendations using one of three kits/approaches: (1) the 
Paired-End Sample Prep Kit (Illumina Inc, San Diego, CA) for sequencing on the HiSeq 2500 (2x125 bp reads) (2) Kapa Auto 
Illumina (Kapa Biosystems, Woburn, MA) for sequencing on the HiSeq 2500 V4 1Tb (2x125 bp reads) and (3) Kapa Auto Illumina 
(Kapa Biosystems, Woburn, MA) for sequencing on the HiSeq 4000 (2x150 bp reads). Samples were pooled and captured using one 
of four capture reagents: (1) NimbleGen SeqCap EZ Human Exome Library v3.0 Kit (Roche NimbleGen, Madison, WI) (2) 
NimbleGen SeqCap EZ Human Exome Library v3.0 Kit spiked with a custom capture Integrated DNA technologies (IDT) reagent 
(Griffith et al., 2015a)​ (3) NimbleGen SeqCap EZ HGSC VCRome Kit (Roche NimbleGen, Madison, WI) and (4) xGen Lockdown 
Exome Panel v1.0 (IDT, Coralville, IA).  
Somatic event detection 
The Genome Modeling System (GMS) was used for all analysis, including the somatic variant detection and RNA-seq analysis 
(Griffith et al., 2015b)​. Single nucleotide variants (SNVs) were detected by taking the union of VarScan2 v2.3.6​(Koboldt et al., 2012)​, 
Strelka v1.0.11​(Saunders et al., 2012)​, Mutect v1.1.4​(Cibulskis et al., 2013)​, and SomaticSniper v1.0.4​(Larson et al., 2012)​, and 
filtered using Samtools r982​(Li et al., 2009)​ ([mpileup -BuDS] filtered by var-filter-snv v1 then false-positive-vcf v1). Small 
insertions and deletions (indels) were detected by GATK Somatic Indel Detector (v5336) ​(McKenna et al., 2010)​, VarScan2, Strelka, 
and Mutect. Variants were annotated by the GMS transcript variant annotator against Ensembl v74 and compared to the database of 
curated mutations (DoCM) ​(Ainscough et al., 2016; Chen et al., 2016)​ and COSMIC mutations ​(Forbes et al., 2011)​. All SNVs and 
indels were manually reviewed for removal of false positives according to standard procedures ​(Barnell et al., 2018)​. 
Analysis of published expression data and random forest classification.  
728 genes were previously used to define four molecular subtypes of HNSCC using this gene expression dataset ​(Walter et al., 2013)​. 
These 728 genes (HGNC symbols) mapped to 797 gene identifiers in the Ensembl v90 database. The union of Ensembl gene 
identifiers was taken across three experiments - Walter et al., the TCGA HNSCC dataset ​(Cancer Genome Atlas Network, 2015)​, and 
this study (hereafter referred to as WUSM) - to produce a final list of 638 Ensembl gene IDs. The microarray probe-level intensity 
files (containing log2-transformed, normexp background-corrected, loess-normalized values) from Walter et al. (GSE39366, n=138) 
were gene median-normalized ​(Walter et al., 2013)​. Gene expression data (FPKM) from the TCGA HNSCC cohort (n=277) was 
log2-transformed and gene median-normalized ​(Cancer Genome Atlas Network, 2015)​. The randomForest R package v.4.6-12 was 
used to build a classifier using the 638 genes and the 138 samples from the Walter et al. dataset (GSE39366) based upon their 
previously reported molecular subtypes . The classifier was defined using 1,001 trees and downsampling to the minimum sample size 
per molecular subtype (n=29). Model performance was validated using the randomForest package by applying the classifier to the 
TCGA dataset and comparing predictions to the previously reported molecular subtypes. Tumor RNA expression (FPKM) reported in 
this study (WUSM; n=16) was log2-transformed and gene median-normalized, and molecular subtypes were predicted by applying the 
classifier to these expression values. 
Genes associated with cancer-associated fibroblasts (CAFs) were used to compare classified mesenchymal tumors with others, based 
upon the transformed/gene median-normalized expression values within each dataset (Walter et al., TCGA, WUSM). Puram et al. 
showed that expression of 449 genes can be used to describe a signature associated with cancer-associated fibroblasts (CAFs) that 
defines the mesenchymal molecular subtype of head and neck cancers ​(Puram et al., 2017)​. These 449 genes mapped to 412 Ensembl 
gene identifiers assessed in the Walter et al., TCGA, and WUSM datasets. The 412 genes associated with CAF expression signatures 
were gene-median centered (GMC) with respect to each dataset, and then these 412 genes were summarized per sample by the median 
GMC value (denoted as ‘CAF signature’ in Figure 5). 
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